Cambrex Corp. has completed its $425 million acquisition of Halo Pharma, it announced Wednesday.
The takeover, previously announced in July, will see the East Rutherford-based maker of pharmaceutical ingredients take over the dosage form manufacturing company located in Whippany and Quebec.
“This acquisition is well-aligned with our commitment to providing best-in-class services to meet the needs of our global pharmaceutical, biotech and generic customers and the combined business creates a leading small molecule CDMO with both API and finished dosage development and manufacturing capabilities,” Steve Klosk, Cambrex’s CEO and president, said in a prepared statement.
The former Halo facilities have been dubbed Cambrex Whippany and Cambrex Mirabel. They provide formulation development and clinical and commercial manufacturing services.
“This acquisition expands our manufacturing footprint with the addition of two state-of-the-art, GMP-compliant manufacturing facilities in North America, both with a strong reputation for quality and excellent track records with regulatory approvals,” Chief Operating Officer Shawn Cavanagh said in a statement. “… We look forward to welcoming the 450-person workforce in joining our existing 1,200 experts across the United States and Europe.”
